PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance
| Autor: | Spyridon Savvanis, Lourdes Victoria Quiles-Sánchez, Anna Garmpi, Evangelos Diamantis, Georgios Kyriakos, Nikolaos Garmpis, Errika Voutyritsa, Paraskevi Farmaki, Alexandros Patsouras, Athanasia Stelianidi, Christos Damaskos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Weakness medicine.medical_specialty Statin medicine.drug_class Review Article Antibodies Monoclonal Humanized General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans PCSK9 Inhibitors Alirocumab Pharmacology biology business.industry PCSK9 Anticholesteremic Agents Subtilisin Evolocumab 030220 oncology & carcinogenesis biology.protein Treatment strategy lipids (amino acids peptides and proteins) medicine.symptom Antibody Hydroxymethylglutaryl-CoA Reductase Inhibitors Proprotein Convertase 9 business |
| Zdroj: | In Vivo |
| Popis: | Background Statin intolerance refers to the inability of a patient to tolerate statin therapy, presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous patients are not treated with suitable statin-based therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDL-C) is not achieved, resulting in patients at a high risk for cardiovascular events, requiring an alternative lipid-lowering treatment. Common treatments manage to reduce the LDL-C level by up to 20%. Recently, new alternative treatment options have been proved to lower the LDL-C level by up to 70%. These treatment strategies are based on human monoclonal antibodies against protein convertase subtilisin/kexin 9 (PCSK9). Materials and methods Herein, we review the efficiency of anti-PCSK9 in treatment of hypercholesterolemic patients with statin intolerance. We focused on the use of PCSK9 inhibitors in statin-intolerant patients and we estimated the clinical results concerning the reduction of the mean LDL-C concentration and the side effects that were observed. Results In the majority of cases, treatment strategy based on PCSK9 was successful and achieved the end-points. Conclusion PCSK9 inhibition can be considered as a treatment of option for lipid-lowering in statin-intolerant patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|